AveXis (AVXS) shares are over 1% higher Monday morning after the clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases presented positive interim data from its trial of AVXS-101 in spinal muscular atrophy.
Two-thirds of patients in Cohort 2 had achieved the ability to sit unassisted, including one patient whose achievement of this milestone was confirmed after September 15. In Cohort 2, 11 of 12 patients achieved head control, 7 of 12 patients could roll over completely and 11 of 12 patients could sit with support.
Two patients are now walking independently, including one whose achievement of this milestone was confirmed after September 15. These two patients each achieved earlier and important developmental milestones such as crawling, standing with support, standing alone and walking with support.
The shares recently traded at $48.16 nearing the top of a 52-week range of $16.11 – $49.41.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.